PDF herunterladen
Nuklearmedizin 2009; 48(05): N52-N54
DOI: 10.1055/s-0037-1621112
Case report
Schattauer GmbH

68Ga-DOTATOC-PET/CT detects neuroendocrine differentiation of prostate cancer metastases

M. Souvatzoglou
1   Department of Nuclear Medicine, Klinikumrechts-der-Isar, Muenchen, Germany
,
T. Maurer
2   Department of Urology, Klinikum-rechts-der-Isar, Muenchen, Germany
,
U. Treiber
2   Department of Urology, Klinikum-rechts-der-Isar, Muenchen, Germany
,
G. Weirich
3   Institute of Pathology, Klinikum-rechts-der-Isar, Muenchen, Germany
,
B. J. Krause
1   Department of Nuclear Medicine, Klinikumrechts-der-Isar, Muenchen, Germany
,
M. Essler
1   Department of Nuclear Medicine, Klinikumrechts-der-Isar, Muenchen, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 24. Februar 2009

accepted in revised form: 12. Mai 2009

Publikationsdatum:
20. Januar 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

 

 

  • References

  • 1 Amorino GP, Parsons SJ. Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 2004; 14: 287-300.
    CrossrefPubMedSuche in Google Scholar
  • 2 Bostwick DG, Dousa MK, Crawford BG, Wollan PC. Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Surg Pathol 1994; 18: 1240-1246.
    CrossrefPubMedSuche in Google Scholar
  • 3 Debes JD, Tindall DJ. Mechanisms of androgen-re- fractory prostate cancer. N Engl J Med 2004; 351: 1488-1490.
    CrossrefPubMedSuche in Google Scholar
  • 4 Elgeti F, Amthauer H, Denecke T. et al. Incidental detection of breast cancer by 68Ga-DOTATOC- PET/CT in women suffering from neuroendocrine tumours. Nuklearmedizin 2008; 47: 261-265.
    Thieme ConnectPubMedSuche in Google Scholar
  • 5 Hofmann M, Maecke H, Borner R. et al. Biokinetics and imaging with the somatostatin receptor PET radioligand [68Ga]-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28: 1751-1757.
    CrossrefPubMedSuche in Google Scholar
  • 6 Meisetschlager G, Poethko T, Stahl A. et al. Gluc- Lys([18F]FP)-TOCA PET in patients with SSTR- positive tumors: biodistribution and diagnostic evaluation compared with [mIn]DTPA-octreotide. J Nucl Med 2006; 47: 566-573.
    PubMedSuche in Google Scholar
  • 7 Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 1992; 147: 804-807.
    CrossrefPubMedSuche in Google Scholar
  • 8 Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006; 36: 228-247.
    CrossrefPubMedSuche in Google Scholar
  • 9 Schron DS, Gipson T, Mendelsohn G. The histogenesis of small cell carcinoma of the prostate. An im- munohistochemical study. Cancer 1984; 53: 2478-2480.
    Suche in Google Scholar
  • 10 Sciarra A, Mariotti G, Gentile V. et al. Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?. BJU Int 2003; 91: 438-445.
    CrossrefPubMedSuche in Google Scholar
  • 11 Solvin SF. Nat Clin Pract Urology. 2006 3. 138-144.
    PubMedSuche in Google Scholar
  • 12 Têtu B, Ro JY, Ayala AG, Johnson DE. et al. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 1987; 59: 1803-1809.
    CrossrefPubMedSuche in Google Scholar